- Home
- ONEG vs MCRB Comparison
ONEG vs MCRB Comparison
Compare ONEG & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONEG | MCRB |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | Hong Kong | United States |
| Employees | 26 | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 139.7M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ONEG | MCRB |
|---|---|---|
| Price | $1.49 | $8.86 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | ★ 334.8K | 97.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 2.40 |
| Revenue | N/A | ★ $126,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.64 |
| Revenue Growth | N/A | ★ 1672.24 |
| 52 Week Low | $1.00 | $0.36 |
| 52 Week High | $13.50 | $29.98 |
Technical Indicators
Market Signals| Indicator | ONEG | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 33.09 | 30.78 |
| Support Level | N/A | $7.12 |
| Resistance Level | $2.28 | $16.14 |
| Average True Range (ATR) | 0.77 | 0.99 |
| MACD | -0.24 | -0.10 |
| Stochastic Oscillator | 2.88 | 13.01 |
Price Performance
Historical ComparisonAbout ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.